{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:38:01Z","timestamp":1792697881921,"version":"4.5.0"},"reference-count":113,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2022RC278"],"award-info":[{"award-number":["2022RC278"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>\n                    Patients with severe carbapenem-resistant\n                    <jats:italic>Acinetobacter baumannii<\/jats:italic>\n                    (CRAB) infections currently face significant treatment challenges. When patients display signs of infection and the clinical suspicion of CRAB infections is high, appropriate treatment should be immediately provided. However, current treatment plans and clinical data for CRAB are limited. Inherent and acquired resistance mechanisms, as well as host factors, significantly restrict options for empirical medication. Moreover, inappropriate drug coverage can have detrimental effects on patients. Most existing studies have limitations, such as a restricted sample size, and are predominantly observational or non-randomized, which report significant variability in patient infection severity and comorbidities. Therefore, a gold-standard therapy remains lacking. Current and future treatment options of infections due to CRAB were described in this review. The dose and considerable side effects restrict treatment options for polymyxins, and high doses of ampicillin-sulbactam or tigecycline appear to be the best option at the time of initial treatment. Moreover, new drugs such as durlobactam and cefiderocol have substantial therapeutic capabilities and may be effective salvage treatments. Bacteriophages and antimicrobial peptides may serve as alternative treatment options in the near future. The advantages of a combination antimicrobial regimen appear to predominate those of a single regimen. Despite its significant nephrotoxicity, colistin is considered a primary treatment and is often used in combination with antimicrobials, such as tigecycline, ampicillin-sulbactam, meropenem, or fosfomycin. The Infectious Diseases Society of America (IDSA) has deemed high-dose ampicillin-sulbactam, which is typically combined with high-dose tigecycline, polymyxin, and other antibacterial agents, the best option for treating serious CRAB infections. A rational combination of drug use and the exploration of new therapeutic drugs can alleviate or prevent the effects of CRAB infections, shorten hospital stays, and reduce patient mortality.\n                  <\/jats:p>","DOI":"10.3389\/fcimb.2024.1395260","type":"journal-article","created":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T04:15:13Z","timestamp":1721103313000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":62,"title":["Treatment of infections caused by carbapenem-resistant Acinetobacter baumannii"],"prefix":"10.3389","volume":"14","author":[{"given":"Siqin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingfang","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1007\/s40121-021-00541-4","article-title":"Contemporary perspective on the treatment of acinetobacter baumannii infections: insights from the society of infectious diseases pharmacists","volume":"10","author":"Abdul-Mutakabbir","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"B2","first-page":"311","article-title":"Efficacy of loading dose of colistin in Acinetobacter baumannii ventilator-associated pneumonia","volume":"25","author":"Alp","year":"2017","journal-title":"Infez. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1177\/1060028014528306","article-title":"Rifampicin as adjunct to colistin therapy in the treatment of multidrug-resistant Acinetobacter baumannii","volume":"48","author":"Al-Shaer","year":"2014","journal-title":"Ann. Pharmacother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3390\/pathogens12020286","article-title":"Acinetobacter baumanniiEfficacy of fosfomycin-containing regimens for treatment of bacteremia due to pan-drug resistant in critically ill patients: A case series study","volume":"12","author":"Assimakopoulos","year":"2023","journal-title":"Pathogens"},{"key":"B5","first-page":"11","article-title":"Triple combination therapy with high-dose ampicillin\/sulbactam, high-dose tigecycline and colistin in the treatment of ventilator-associated pneumonia caused by pan-drug resistant Acinetobacter baumannii: a case series study","volume":"27","author":"Assimakopoulos","year":"2019","journal-title":"Infez. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1017\/S095026881200194X","article-title":"Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"141","author":"Aydemir","year":"2013","journal-title":"Epidemiol. Infect."},{"key":"B7","doi-asserted-by":"publisher","first-page":"6774","DOI":"10.1128\/AAC.00839-16","article-title":"In Vitro Synergistic Activity of Antimicrobial Agents in Combination against Clinical Isolates of Colistin-Resistant Acinetobacter baumannii","volume":"60","author":"Bae","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1038\/s41564-019-0480-z","article-title":"Antibiotic combinations that exploit heteroresistance to multiple drugs effectively control infection","volume":"4","author":"Band","year":"2019","journal-title":"Nat. Microbiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s40121-022-00597-w","article-title":"Carbapenem-resistant acinetobacter baumannii: colonization, infection and current treatment options","volume":"11","author":"Bartal","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3390\/antibiotics10060652","article-title":"Cefiderocol-based combination therapy for \"Difficult-to-treat\" Gram-negative severe infections: real-life case series and future perspectives","volume":"10","author":"Bavaro","year":"2021","journal-title":"Antibiot. (Basel)."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1007\/s40121-023-00854-6","article-title":"Cefiderocol versus colistin for the treatment of carbapenem-resistant acinetobacter baumannii complex bloodstream infections: A retrospective, propensity-score adjusted, monocentric cohort study","volume":"12","author":"Bavaro","year":"2023","journal-title":"Infect. Dis. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"10.1128\/aac.01680-20","DOI":"10.1128\/AAC.01680-20","article-title":"In VitroMinocycline Alone and in Combination with Polymyxin B, Meropenem, and Sulbactam against Carbapenem-Susceptible and -Resistant Acinetobacter baumannii in an Pharmacodynamic Model","volume":"65","author":"Beganovic","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jinf.2008.04.002","article-title":"Efficacy and safety of high-dose ampicillin\/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"56","author":"Betrosian","year":"2008","journal-title":"J. Infect."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-102","article-title":"Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis","volume":"14","author":"Chuang","year":"2014","journal-title":"BMC Infect. Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.diagmicrobio.2016.09.010","article-title":"Colistin enhances therapeutic efficacy of daptomycin or teicoplanin in a murine model of multiresistant Acinetobacter baumannii sepsis","volume":"86","author":"Cirioni","year":"2016","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40121-014-0051-9","article-title":"A review of novel combinations of colistin and lipopeptide or glycopeptide antibiotics for the treatment of multidrug-resistant Acinetobacter baumannii","volume":"3","author":"Claeys","year":"2014","journal-title":"Infect. Dis. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.jiph.2022.07.006","article-title":"Cefiderocol use in Gram negative infections with limited therapeutic options: Is combination therapy the key","volume":"15","author":"Corcione","year":"2022","journal-title":"J. Infect. Public Health"},{"key":"B19","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13613-020-00715-2","article-title":"Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections","volume":"10","author":"De Pascale","year":"2020","journal-title":"Ann. Intensive Care"},{"key":"B20","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/cid\/cit253","article-title":"Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial","volume":"57","author":"Durante-Mangoni","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02142-21","article-title":"Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant acinetobacter baumannii","volume":"66","author":"Falcone","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"B22","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jgar.2022.05.011","article-title":"In vitro activity of sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii and mechanisms of resistance","volume":"30","author":"Findlay","year":"2022","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"B23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1159\/000356004","article-title":"Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii","volume":"59","author":"Garnacho-Montero","year":"2014","journal-title":"Chemotherapy"},{"key":"B24","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s15010-022-01933-5","article-title":"Case series of cefiderocol for salvage therapy in carbapenem-resistant Gram-negative infections","volume":"51","author":"Gavaghan","year":"2023","journal-title":"Infection"},{"key":"B25","doi-asserted-by":"publisher","first-page":"4577","DOI":"10.1021\/acs.jmedchem.7b00102","article-title":"Targeted antibiotic delivery: selective siderophore conjugation with daptomycin confers potent activity against multidrug resistant Acinetobacter baumannii both in vitro and in vivo","volume":"60","author":"Ghosh","year":"2017","journal-title":"J. Med. Chem."},{"key":"B26","doi-asserted-by":"publisher","first-page":"S381","DOI":"10.1093\/cid\/ciu593","article-title":"Bad bugs need old drugs: a stewardship program's evaluation of minocycline for multidrug-resistant Acinetobacter baumannii infections","author":"Goff","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s40265-016-0636-6","article-title":"Intravenous minocycline: A review in acinetobacter infections","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac092","article-title":"Acinetobacter baumanniiNovel combination therapy for extensively drug-resistant necrotizing pneumonia complicated by empyema: A case report","volume":"9","author":"Holger","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1093\/jac\/dky425","article-title":"In vitro activities of cefiderocol, ceftolozane\/tazobactam, ceftazidime\/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan","volume":"74","author":"Hsueh","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2017.02659","article-title":"Acinetobacter baumanniiPhage therapy as a promising new treatment for lung infection caused by carbapenem-resistant in mice","volume":"8","author":"Hua","year":"2017","journal-title":"Front. Microbiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"8841","DOI":"10.1016\/j.biomaterials.2012.08.026","article-title":"Cationic amphiphilic alpha-helical peptides for the treatment of carbapenem-resistant Acinetobacter baumannii infection","volume":"33","author":"Huang","year":"2012","journal-title":"Biomaterials"},{"key":"B32","doi-asserted-by":"publisher","first-page":"10.1128\/aac.01110-18","DOI":"10.1128\/AAC.01110-18","article-title":"Acinetobacter baumanniiNew Treatment Options against Carbapenem-Resistant Infections","volume":"63","author":"Isler","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2180-12-156","article-title":"Isolation and characterization of ZZ1, a novel lytic phage that infects Acinetobacter baumannii clinical isolates","volume":"12","author":"Jin","year":"2012","journal-title":"BMC Microbiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s13054-017-1916-6","article-title":"Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis","volume":"21","author":"Jung","year":"2017","journal-title":"Crit. Care"},{"key":"B35","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s15010-020-01520-6","article-title":"Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems","volume":"48","author":"Karakonstantis","year":"2020","journal-title":"Infection"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.3390\/antibiotics12121729","article-title":"Acinetobacter baumanniiCefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant","volume":"12","author":"Karruli","year":"2023","journal-title":"Antibiot. (Basel)."},{"key":"B37","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1177\/0885066617725694","article-title":"Efficacy and safety of high loading dose of colistin in multidrug-resistant Acinetobacter baumannii: a prospective cohort study","volume":"34","author":"Katip","year":"2019","journal-title":"J. Intensive Care Med."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13020162","article-title":"Clinical efficacy and nephrotoxicity of colistin alone versus colistin plus vancomycin in critically ill patients infected with carbapenem-resistant Acinetobacter baumannii: a propensity score-matched analysis","volume":"13","author":"Katip","year":"2021","journal-title":"Pharmaceutics"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14061266","article-title":"Effectiveness and nephrotoxicity of loading dose colistin\u2013meropenem versus loading dose colistin\u2013imipenem in the treatment of carbapenem-resistant Acinetobacter baumannii infection","volume":"14","author":"Katip","year":"2022","journal-title":"Pharmaceutics"},{"key":"B40","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2147\/IDR.S144314","article-title":"Clinical outcomes and nephrotoxicity of colistin loading dose for treatment of extensively drug-resistant Acinetobacter baumannii in cancer patients","volume":"10","author":"Katip","year":"2017","journal-title":"Infect. Drug Resist."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14010031","article-title":"Clinical efficacy and nephrotoxicity of the loading dose colistin for the treatment of carbapenem-resistant Acinetobacter baumannii in critically ill patients","volume":"14","author":"Katip","year":"2021","journal-title":"Pharmaceutics"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","article-title":"Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/jac\/dkx368","article-title":"Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis","volume":"73","author":"Kengkla","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"B44","doi-asserted-by":"publisher","first-page":"901","DOI":"10.2217\/cer-2018-0037","article-title":"Meropenem\/colistin versus meropenem\/ampicillin-sulbactam in the treatment of carbapenem-resistant pneumonia","volume":"7","author":"Khalili","year":"2018","journal-title":"J. Comp. Eff. Res."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106882","article-title":"Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence","volume":"62","author":"Kollef","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B46","doi-asserted-by":"publisher","first-page":"12520","DOI":"10.3390\/ijms222212520","article-title":"Acinetobacter baumanniiAntiseptic 9-Meric Peptide with Potency against Carbapenem-Resistant Infection","volume":"22","author":"Krishnan","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2016.01590","article-title":"Acinetobacter baumanniiCharacterization and testing the efficiency of phage as an antibacterial agent","volume":"7","author":"Kusradze","year":"2016","journal-title":"Front. Microbiol."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.001136","article-title":"Polymyxin and lipopeptide antibiotics: membrane-targeting drugs of last resort","volume":"168","author":"Ledger","year":"2022","journal-title":"Microbiol. (Reading)."},{"key":"B49","doi-asserted-by":"publisher","first-page":"Undefined","DOI":"10.1128\/AAC.01268-16","article-title":"High-dose ampicillin-sulbactam combinations combat polymyxin-resistant acinetobacter baumannii in a hollow-fiber infection model","volume":"61","author":"Lenhard","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B50","doi-asserted-by":"publisher","first-page":"908.e1","DOI":"10.1016\/j.cmi.2017.10.033","article-title":"Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii","volume":"24","author":"Liang","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2019.100966","article-title":"Acinetobacter baumannii -Therapeutic drug monitoring-guided high dose meropenem therapy of a multidrug resistant A case report","volume":"29","author":"Liebchen","year":"2020","journal-title":"Respir. Med. Case Rep."},{"key":"B52","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.resmic.2010.03.007","article-title":"Isolation and characterization of phi AB2: a novel bacteriophage of Acinetobacter baumannii","volume":"161","author":"Lin","year":"2010","journal-title":"Res. Microbiol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jgar.2020.08.021","article-title":"Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: A systematic review and network meta-analysis","volume":"24","author":"Liu","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"B54","doi-asserted-by":"publisher","first-page":"i21","DOI":"10.1093\/jacamr\/dlab055","article-title":"Acinetobacter baumanniiCompassionate use of cefiderocol for carbapenem-resistant prosthetic joint infection","volume":"3","author":"Mabayoje","year":"2021","journal-title":"JAC. Antimicrob. Resist."},{"key":"B55","doi-asserted-by":"publisher","first-page":"Undefined","DOI":"10.3390\/antibiotics12010049","article-title":"Intravenous fosfomycin: A potential good partner for cefiderocol. Clinical experience and considerations","volume":"12","author":"Marino","year":"2022","journal-title":"Antibiot. (Basel)."},{"key":"B56","doi-asserted-by":"publisher","first-page":"984","DOI":"10.3390\/microorganisms11040984","article-title":"Acinetobacter baumanniiCefiderocol-Based versus Colistin-Based Regimens for Severe Carbapenem-Resistant Infections: A Propensity Score-Weighted, Retrospective Cohort Study during the First Two Years of the COVID-19 Pandemic","volume":"11","author":"Mazzitelli","year":"2023","journal-title":"Microorganisms"},{"key":"B57","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.ijid.2020.08.010","article-title":"Clinical efficacy and pharmacokinetics of colistimethate sodium and colistin in critically ill patients in an Indian hospital with high endemic rates of multidrug-resistant Gram-negative bacterial infections: A prospective observational study","volume":"100","author":"Moni","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"B58","doi-asserted-by":"publisher","first-page":"10.1128\/aac.01699-19","DOI":"10.1128\/AAC.01699-19","article-title":"In vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017","volume":"64","author":"Morrissey","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B59","doi-asserted-by":"publisher","first-page":"10.1128\/aac.01111-19","DOI":"10.1128\/AAC.01111-19","article-title":"Phenotypic, biochemical and genetic analysis of KPC-41, a KPC-3 variant conferring resistance to ceftazidime-avibactam and exhibiting reduced carbapenemase activity","volume":"63","author":"Mueller","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B60","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"B61","doi-asserted-by":"publisher","first-page":"26516","DOI":"10.1073\/pnas.1909585117","article-title":"Pseudomonas aeruginosaThe antimicrobial peptide ZY4 combats multidrug-resistant and infection","volume":"116","author":"Mwangi","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B62","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ijantimicag.2015.11.011","article-title":"Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis","volume":"47","author":"Ni","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B63","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/S1473-3099(19)30574-2","article-title":"Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial","volume":"20","author":"Niederman","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"B64","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13756-019-0502-x","article-title":"Acinetobacter baumanniiComparison of Tigecycline or Cefoperazone\/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant","volume":"8","author":"Niu","year":"2019","journal-title":"Antimicrob. Resist. Infect. Control."},{"key":"B65","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1093\/jac\/dkaa508","article-title":"In vitro pharmacodynamics of omadacycline against Escherichia coli and Acinetobacter baumannii","volume":"76","author":"Noel","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"B66","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/phar.2607","article-title":"Treatment of patients with serious infections due to carbapenem-resistant Acinetobacter baumannii: How viable are the current options","volume":"41","author":"O'Donnell","year":"2021","journal-title":"Pharmacotherapy"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02501-12","article-title":"Activities of vancomycin-containing regimens against colistin-resistant Acinetobacter baumannii clinical strains","volume":"57","author":"O'Hara","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"B68","first-page":"205","article-title":"Clinical and in vitro efficacy of colistin plus vancomycin and rifampin against colistin-resistant Acinetobacter baumannii causing ventilator-associated pneumonia","volume":"40","author":"Oliva","year":"2017","journal-title":"New Microbiol."},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24050886","article-title":"In-vitro evaluation of different antimicrobial combinations with and without colistin against carbapenem-resistant Acinetobacter baumannii","volume":"24","author":"Oliva","year":"2019","journal-title":"Molecules"},{"key":"B70","doi-asserted-by":"publisher","first-page":"60","DOI":"10.7150\/jbji.42448","article-title":"Acinetobacter baumanniiTigecycline versus colistin in the treatment of carbapenem-resistant complex osteomyelitis","volume":"5","author":"Oliveira","year":"2020","journal-title":"J. Bone Jt. Infect."},{"key":"B71","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jgar.2018.11.016","article-title":"Colistin monotherapy versus colistin\/rifampicin combination therapy in pneumonia caused by colistin-resistant Acinetobacter baumannii: A randomised controlled trial","volume":"17","author":"Park","year":"2019","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10080903","article-title":"Clinical outcomes and safety of meropenem\u2013colistin versus meropenem\u2013tigecycline in patients with carbapenem-resistant Acinetobacter baumannii pneumonia","volume":"10","author":"Park","year":"2021","journal-title":"Antibiotics"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlab174","article-title":"Acinetobacter baumanniiCefiderocol treatment for carbapenem-resistant infection in the ICU during the COVID-19 pandemic: a multicentre cohort study","volume":"3","author":"Pascale","year":"2021","journal-title":"JAC. Antimicrob. Resist."},{"key":"B74","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1128\/AAC.04808-14","article-title":"Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii","volume":"59","author":"Penwell","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B76","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00232-021-00175-0","article-title":"The antibiotic peptide daptomycin functions by reorganizing the membrane","volume":"254","author":"Pokorny","year":"2021","journal-title":"J. Membr. Biol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/psc.2978","article-title":"Synergistic activity profile of an antimicrobial peptide against multidrug-resistant and extensively drug-resistant strains of Gram-negative bacterial pathogens","volume":"23","author":"Pollini","year":"2017","journal-title":"J. Pept. Sci."},{"key":"B78","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ijantimicag.2018.10.024","article-title":"Daptomycin as adjunctive treatment for experimental infection by Acinetobacter baumannii with resistance to colistin","volume":"53","author":"Poulakou","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00824-21","article-title":"Critically ill patient with multidrug-resistant acinetobacter baumannii respiratory infection successfully treated with intravenous and nebulized bacteriophage therapy","volume":"66","author":"Rao","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"B80","doi-asserted-by":"publisher","first-page":"5806","DOI":"10.1128\/AAC.02877-15","article-title":"Personalized therapeutic cocktail of wild environmental phages rescues mice from acinetobacter baumannii wound infections","volume":"60","author":"Regeimbal","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B81","doi-asserted-by":"publisher","first-page":"S374","DOI":"10.1093\/cid\/ciu613","article-title":"A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections","volume":"59","author":"Ritchie","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"B82","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jinf.2011.10.007","article-title":"Impact of heteroresistance to colistin in meningitis caused by Acinetobacter baumannii","volume":"64","author":"Rodr\u00edguez","year":"2012","journal-title":"J. Infect."},{"key":"B83","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s40121-020-00357-8","article-title":"Efficacy of a fosfomycin-containing regimen for treatment of severe pneumonia caused by multidrug-resistant acinetobacter baumannii: A prospective, observational study","volume":"10","author":"Russo","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"B84","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1021\/acschembio.0c00091","article-title":"Vancomycin derivative inactivates carbapenem-resistant Acinetobacter baumannii and induces autophagy","volume":"15","author":"Sarkar","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.00954-17","article-title":"Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection","volume":"61","author":"Schooley","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1177\/10600280221085551","article-title":"VersusEfficacy of eravacycline best previously available therapy for adults with pneumonia due to difficult-to-treat resistant (DTR)","volume":"56","author":"Scott","year":"2022","journal-title":"Ann. Pharmacother."},{"key":"B87","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jgar.2022.08.002","article-title":"Global update on the in vitro activity of tigecycline and comparators against isolates of Acinetobacter baumannii and rates of resistant phenotypes, (2016-2018)","volume":"31","author":"Seifert","year":"2022","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"B88","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jgar.2021.01.018","article-title":"What is the optimal antibiotic treatment strategy for carbapenem-resistant Acinetobacter baumannii (CRAB)? A multicentre study in Korea","volume":"24","author":"Seok","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01612-17","article-title":"Kinetics of sulbactam hydrolysis by \u03b2-lactamases, and kinetics of \u03b2-lactamase inhibition by sulbactam","volume":"61","author":"Shapiro","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B90","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.1093\/cid\/ciad094","article-title":"Navigating available treatment options for carbapenem-resistant acinetobacter baumannii-calcoaceticus complex infections","volume":"76","author":"Shields","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"B91","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1099\/jmm.0.000920","article-title":"Synergistic activity of polymyxin B combined with vancomycin against carbapenem-resistant and polymyxin-resistant Acinetobacter baumannii: First in vitro study","volume":"68","author":"Shinohara","year":"2019","journal-title":"J. Med. Microbiol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"5598","DOI":"10.1128\/AAC.02435-13","article-title":"Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections","volume":"58","author":"Sirijatuphat","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B93","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"B94","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/cid\/ciac268","article-title":"Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum \u03b2-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)","volume":"75","author":"Tamma","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"B95","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases Society of America Guidance on the Treatment of AmpC \u03b2-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"B96","doi-asserted-by":"publisher","first-page":"ciad428","DOI":"10.1093\/cid\/ciad428","article-title":"Infectious diseases society of america 2023 guidance on the treatment of antimicrobial resistant gram-negative infections","author":"Tamma","year":"2023","journal-title":"Clin. Infect. Dis"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.631585","article-title":"Clinical experience of personalized phage therapy against carbapenem-resistant Acinetobacter baumannii lung infection in a patient with chronic obstructive pulmonary disease","volume":"11","author":"Tan","year":"2021","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3390\/bioengineering10010035","article-title":"Acinetobacter baumanniiRecent advances in phage-based therapeutics for multi-drug resistant","volume":"10","author":"Tan","year":"2022","journal-title":"Bioengineering. (Basel)."},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2016.01402","article-title":"Enhanced antibacterial activity of acinetobacter baumannii bacteriophage \u00d8ABP-01 endolysin (LysABP-01) in combination with colistin","volume":"7","author":"Thummeepak","year":"2016","journal-title":"Front. Microbiol."},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlad078","article-title":"Acinetobacter baumanniiSalvage therapy with sulbactam\/durlobactam against cefiderocol-resistant in a critically ill burn patient: clinical challenges and molecular characterization","volume":"5","author":"Tiseo","year":"2023","journal-title":"JAC. Antimicrob. Resist."},{"key":"B101","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","article-title":"International consensus guidelines for the optimal use of the polymyxins: endorsed by the american college of clinical pharmacy (ACCP), european society of clinical microbiology and infectious diseases (ESCMID), infectious diseases society of america (IDSA), international society for anti-infective pharmacology (ISAP), society of critical care medicine (SCCM), and society of infectious diseases pharmacists (SIDP)","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"B102","unstructured":"Highlights of Prescribing Information: Xacduro (sulbactam\/durlobactam)2023"},{"key":"B103","unstructured":"Highlights of Prescribing Information: Fetroja (Cefiderocol)2019"},{"key":"B104","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1021\/acsinfecdis.1c00318","article-title":"Vancomyxins: Vancomycin-polymyxin nonapeptide conjugates that retain anti-Gram-positive activity with enhanced potency against Gram-negative strains","volume":"7","author":"Van Groesen","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijantimicag.2017.05.016","article-title":"Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: a systematic review and meta-analysis","volume":"51","author":"Vardakas","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.12.009","article-title":"Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins","volume":"27","author":"Wagenlehner","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"B107","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1128\/CMR.00058-16","article-title":"Clinical and Pathophysiological overview of acinetobacter infections: a century of challenges","volume":"30","author":"Wong","year":"2017","journal-title":"Clin. Microbiol. Rev."},{"key":"B108","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1080\/22221751.2021.1902754","article-title":"Acinetobacter baumanniiPre-optimized phage therapy on secondary infection in four critical COVID-19 patients","volume":"10","author":"Wu","year":"2021","journal-title":"Emerg. Microbes Infect."},{"key":"B109","doi-asserted-by":"publisher","first-page":"S805","DOI":"10.1093\/ofid\/ofaa439.1806","article-title":"Synergistic effect of cefiderocol with other antibiotics against PER-producing Acinetobacter baumannii isolates from the multinational SIDERO-WT studies","volume":"7","author":"Yamano","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"B110","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1159\/000486117","article-title":"Phage abp1 rescues human cells and mice from infection by pan-drug resistant acinetobacter baumannii","volume":"44","author":"Yin","year":"2017","journal-title":"Cell Physiol. Biochem."},{"key":"B111","doi-asserted-by":"publisher","first-page":"e0092421","DOI":"10.1128\/AAC.00924-21","article-title":"Extensively drug-resistant acinetobacter baumannii nosocomial pneumonia successfully treated with a novel antibiotic combination","volume":"65","author":"Zaidan","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"B112","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jmii.2023.01.017","article-title":"Guidelines for the diagnosis, treatment, prevention and control of infections caused by carbapenem-resistant gram-negative bacilli","volume":"56","author":"Zeng","year":"2023","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s12325-020-01235-y","article-title":"Effectiveness and safety of high dose tigecycline for the treatment of severe infections: A systematic review and meta-analysis","volume":"37","author":"Zha","year":"2020","journal-title":"Adv. Ther."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2024.1395260\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T04:15:21Z","timestamp":1721103321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2024.1395260\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,18]]},"references-count":113,"alternative-id":["10.3389\/fcimb.2024.1395260"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2024.1395260","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,18]]},"article-number":"1395260"}}